NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, with some of the lowest mortality rates in the nation. According to U.S News and World Report, NYU Langone Health has more No. 1–ranked specialties than any other medical center in the U.S. We are proud to be named on the USNWR Honor Roll of the top 20 hospitals in the nation and among the No. 1 hospitals in the New York area. NYULH offers a comprehensive range of medical services with one high standard of care across 5 inpatient locations, the Perlmutter Cancer Center (ranked among the top 20 cancer centers nationally), and more than 320 outpatient locations across New York and Florida. The system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.

The Laura and Isaac Perlmutter Cancer Center at NYU Langone Health (PCC)—an NCI-designated Comprehensive Cancer Center—is on a substantial growth trajectory with expansion of its clinical and research enterprise across the system. PCC operates 11 clinical locations across Manhattan, Brooklyn, Queens and Long Island, as well as a growing and highly efficient clinical trials program with a robust portfolio of studies, multidisciplinary care and research activities, and outstanding training programs.

Director, Solid Tumor Cell Therapy Program – our expanding cell therapy program seeks a leader in the advancement of novel solid tumor immunotherapy approaches, who can interact effectively with colleagues across disease subtypes and disciplines. Experience/focus in any relevant solid tumor subtype is welcomed.

NYU Langone Health is an equal opportunity employer and committed to inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and will receive consideration.